A personalised mRNA therapy made from each patient's own tumour cut the risk of melanoma returning or death by 42% when added to Keytruda, Merck and Moderna said. The trial covered 1,137 patients whose high-risk melanoma had been surgically removed. At two years, 82.2% were alive and relapse-free, against 70% on Keytruda alone, the companies said.